Inhibitory effect of glycyrrhizin on lipopolysaccharide and d-galactosamine-induced mouse liver injury

European Journal of Pharmacology

Volumn 576, Issue 1-3, 2007, Pages 136-142

  Yoshida, Tsuyoshi ^a   Abe, Kazuki ^a   Ikeda, Tadayuki ^b   Matsushita, Tokiyoshi ^a   Wake, Kenjiro ^b,c   Sato, Tetsuji ^b   Sato, Toshitsugu ^a   Inoue, Hideo ^a  

^a Minophagen Pharmaceutical Co   (Japan)

^b TSURUMI UNIVERSITY   (Japan)

^c Minophagen Pharmaceutical Co Ltd   (Japan)

Author keywords

Alanine aminotransferase; Cytokine; d Galactosamine; Glycyrrhizin; Interleukin 18; Lipopolysaccharide; Liver injury

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; GALACTOSAMINE; GLYCYRRHIZIC ACID; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER INJURY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL;

ALANINE TRANSAMINASE; ANIMALS; CYTOKINES; GALACTOSAMINE; GLYCYRRHIZIC ACID; LIPOPOLYSACCHARIDES; LIVER DISEASES; MALE; MICE; MICE, INBRED BALB C; PROTECTIVE AGENTS;

EID: 35348911302     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.012     Document Type: Article

References (45)

1. Abe N., Ebina T., and Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol. Immunol. 26 (1982) 535-539
2. Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., Koida I., Suzuki Y., Saitoh S., Kobayashi M., and Kumada H. The long term efficacy and glycyrrhizin in chronic hepatitis C patients. Cancer 79 (1997) 1494-1500
3. Beutler B., Milsark I.S., and Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229 (1985) 869-871
4. Chosay J.S., Essani N.A., Dunn C.J., and Jaeschke H. Neutrophil margination and extravasation in sinusoids and venules of liver during endotoxin-induced injury. Am. J. Physiol. 272 5 pt 1 (1997) G1195-G1200
5. Decker K., and Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol., Biochem. Pharmacol. 71 (1974) 77-106
6. Dinarello C.A. Interleukin-18. Methods 19 (1999) 121-132
7. Dinarello C.A., and Fantuzzi G. Interleukin-18 and host defense against infection. J. Infect. Dis. 187 (2003) S370-S384
8. Fukuda T., Mogami A., Tanaka H., Yoshikawa T., Hisadome M., and Komatsu H. Y-40138, a multiple cytokine production modulator, protects against d-galactosamine and lipopolysaccharide-induced hepatitis. Life Sci. 79 (2006) 822-827
9. Galanos C., Freudenberg M.A., and Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 5939-5943
10. Ghayur Y., Banerjee S., Hungunin M., Butler D., Herzog L., Carter A., Quintal J., Sekut L., Talanian R., Paskind M., Wong M., Kamen R., Tracy D., and Allen H. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386 (1997) 619-623
11. Gracie J.A., Robertson S.E., and McInnes I.B. Interleukin-18. J. Leukoc. Biol. 73 (2003) 213-224
12. Ikeda K., Arase Y., Kobayashi M., Saitoh S., Someya T., Hosokawa T., Senzaki H., Akuta N., Suzuki Y., Suzuki F., and Kumada H. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig. Dis. Sci. 51 (2006) 603-609
13. Inoue K., Takano H., Shimada A., Morita T., Yanagisawa R., Sakurai M., Sato M., Yoshino S., and Yoshikawa T. Cytoprotection by interleukin-6 against liver injury induced by lipopolysaccharide. Int. J. Mol. Med. 15 (2005) 221-224
14. Ito M., Sato A., Hirabayashi K., Tanabe F., Shigeta S., Baba M., De Clercq E., Nakashima H., and Yamamoto N. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antivir. Res. 10 (1988) 289-298
15. Jia H.-Y., Zhu S.-H., Ma Y.-J., Chen H.-Y., Yang B.-S., and Cai H.-F. The roles of serum IL-18, IL-10, TNF-α and sIL-2R in patients with chronic hepatitis C. Hepatobiliary Pancreat. Dis. Int. 3 (2002) 378-382
16. Kimura M., Inoue H., Hirabayashi K., Natsume H., and Ogihara M. Glycyrrhizin and some analogues induce growth of primary cultured adult rat hepatocytes via epidermal growth factor receptors. Eur. J. Pharmacol. 431 (2001) 151-161
17. Klein C., Wustefeld T., Heinrich P.C., Streetz K.L., Manns M.P., and Trautwein C. ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism. Eur. J. Immunol. 33 (2003) 2251-2261
18. Kumagai A., Yano S., and Otoma S. Study on the corticoid-like action of glycyrrhizin and the mechanism of its action. Endocr. J. 4 (1957) 17-27
19. Kuroyanagi T., and Saito M. Effect of prednisolone and glycyrrhizin on passive transfer in experimental allergic encephalomyelitis. Arerugi 15 (1966) 67-74 (in Japanese)
20. Leist M., Gantner F., Bohlinger I., Tiegs G., Germann P.G., and Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol. 146 (1995) 1220-1234
21. Lesslauer W., Tabuchi H., Gentz R., Brockhaus M., Schlaeger E.J., Grau G., Piguet P.F., Pointaire P., Vassalli P., and Loetscher H. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. J. Immunol. 21 (1991) 2883-2886
22. Louis H., Moine O.L., Peny M.-O., Gulbis B., Nisol F., Goldman M., and Deviere J. Hepatoprotective role of interleukin 10 in galactosamine/lipopolysaccharide mouse liver injury. Gastroenterology 112 (1997) 935-942
23. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., Vogel W., and Tilg H. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J. Clin. Immunol. 22 (2002) 331-337
24. Marin-Serrano E., Rodriguez-Ramos C., Diaz F., Martin-Herrera L., and Giron-Gonzalez J.A. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J. Viral. Hepatitis 13 (2006) 230-234
25. Nakahira M., Ahn H.-J., Park W.-R., Gao P., Tomura M., Park C.-S., Hamaoka T., Ohta T., Kurimoto M., and Fujiwara H. Synergy of IL-12 and IL-18 for IFN-γgene expression: IL-12-induced STAT4 contributes to IFN-γpromoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J. Immunol. 168 (2002) 1146-1153
26. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamoto H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19 (2001) 423-474
27. Nakao A., Taki S., Yasui M., Kimura Y., Nonami T., Harada A., and Takagi H. The fate of intravenously injected endotoxin in normal rats and in rats with liver failure. Hepatology 19 (1994) 1251-1256
28. Nolan J.P. The role of endotoxin in liver injury. Gastroenterology 69 (1975) 1346-1356
29. Nolan J.P. Intestinal endotoxins as mediators of hepastic injury-an idea whose time has come again. Hepatology 10 (1989) 887-891
30. Nose M., Ito M., Kamimura K., Shimizu M., and Ogihara Y. A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Med. 60 (1994) 136-139
31. Ohuchi K., Kamada Y., Levine L., and Tsurufuji S. Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats. Prostaglandins Med. 7 (1981) 457-463
32. Okamoto T. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. Eur. J. Pharmacol. 387 (2000) 229-232
33. Okamoto T., and Kanda T. Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. Int. J. Mol. Med. 4 (1999) 149-152
34. Okamura H., Tsutsui H., Komatsu T., Yutsudo M., Hakura A., Tanimito T., Torigoe K., Okura T., Nukada Y., Hattori K., Akita H., Namba M., Tanabe F., Konishi K., Fukuda S., and Kurimoto M. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 (1995) 88-91
35. Okimasu E., Moromizato Y., Watanabe S., Sasaki J., Shiraishi N., Morimoto Y.M., Miyahara M., and Utsumi K. Inhibition of phospholipase A2 and platelet aggregation by glycyrrhizin, an antiinflammation drug. Acta Med. Okayama 37 (1983) 385-391
36. Oku H., Nakazato H., Horikawa T., Tsuruta Y., and Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. 446 (2002) 167-176
37. Pompei R., Flore O., Maccialis M.A., Pani A., and Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 281 (1979) 689-690
38. Sakano Y., Takeda K., Tsutsui H., Kaisho T., Nomura F., Okamura H., Nakanishi K., and Akira S. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int. Immunol. 11 (1999) 471-480
39. Sass G., Heinlein S., Agli A., Bang R., Schumann J., and Tiegs G. Cytokine expression in three mouse model of experimental hepatitis. Cytokine 19 (2002) 115-120
40. Tiegs G. Immunotoxicology of host-response-mediated experimental liver injury. J. Hepatol. 21 (1994) 890-903
41. Tiegs G., Wolter M., and Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 38 (1989) 627-631
42. Tracy K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., and Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
43. Yumoto E., Higashi T., Nouso K., Nakatsukasa H., Fujiwara K., Hanafusa T., Yumoto Y., Tanimoto T., Kurimoto M., Tanaka N., and Tsuji T. Serum gamma-interferon-inducing (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J. Gastroenterol. Hepatol. 17 (2002) 285-294
44. van Rossum T.G.J., Vulto A.G., Hop W.C., Brouwer J.T., Niesters H.G., and Schalm S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J. Gastroenterol. Hepatol. 14 (1999) 1039-1099
45. van Rossum T.G.J., Vulto A.G., Hop W.C., and Schalm S.W. Glycyrrhizin induced reduction of ALT in European patients with chronic hepatitis C. Am. J. Gastroenterol. 96 (2001) 2432-2437